GNCA - Analysis Of Genocea's Therapeutic Herpes Vaccine
In my previous Genocea (GNCA) article, I initially expressed my belief therapeutic herpes simplex vaccine GEN-003 produced mixed results and wouldn't enter Phase 3 clinical studies. Due to objections from readers, I edited my article eliminating my opinion because to defend it would require a separate article. While management believes GEN-003 can address unmet needs of herpes simplex patients, I argue GEN-003 clinical data wasn't sufficiently robust to advance into Phase 3 studies. Investors hoping to partner or sell GEN-003 are likely to be disappointed. With GEN-003 unlikely to generate revenue, a